Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome: Prospective, Multicentre, Randomized, Open-label, Blinded-endpoint Clinical Trial

NCT06171061 is registered in ClinicalTrials.gov with Shandong First Medical University as lead sponsor.

NCT NCT06171061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06171061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome: Prospective, Multicentre, Randomized, Open-label, Blinded-endpoint Clinical Trial
Lead sponsor
Shandong First Medical University
Phase
Phase 4
Overall status
Recruiting
Start date
December 18, 2023
Completion date
December 31, 2026
Enrollment
1,200 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

chronic coronary syndrome